Concure Oncology, Inc.

Concure Oncology, Inc. is a healthcare company focused on developing innovative solutions to enhance the quality of life for cancer patients through advanced radiation therapy technologies. Founded in 2014 in Mercer Island, US, Concure Oncology specializes in innovative radiation therapy devices designed to optimize treatment while minimizing harm to healthy tissues. The company has executed three funding deals with the latest funding round occurring on October 29, 2020, where they raised USD 2.

0 mn. The founder's background includes prior entrepreneurial experience, although specific details about other ventures are not provided. Concure Oncology specializes in innovative healthcare solutions aimed at improving the quality of life for cancer patients. The company's primary product offering is a unique radiation therapy device designed to minimize radiation exposure to healthy tissue while effectively targeting cancerous cells.

This technology is especially beneficial for patients undergoing treatment for breast cancer, as it decreases the likelihood of adverse side effects and enhances treatment outcomes. Concure Oncology's client base includes hospitals, cancer treatment centers, and healthcare providers primarily located in North America and select regions in Europe. By focusing on a patient-centric approach, the company addresses critical challenges in oncology treatment, ultimately seeking to improve patient experiences and treatment efficacy. Concure Oncology generates revenue through a direct-to-consumer model and partnerships with healthcare institutions, which often include hospitals and specialized cancer care facilities.

The company’s revenue streams are primarily derived from the sales and leasing of its proprietary radiation therapy devices and associated service agreements. Transaction structures typically consist of long-term contracts with healthcare providers, which may involve upfront payments for equipment combined with ongoing service fees for maintenance and support. While specific pricing details for the therapy devices and service plans are not disclosed, the revenue model aligns with standard practices in the medical device industry, focusing on both device sales and recurring service revenue as key components of their business strategy. Looking forward, Concure Oncology plans to leverage their recent funding of USD 2.

0 mn raised in October 2020 to support the development of new radiation therapy products aimed at addressing specific patient needs. The company is also targeting expansion into select regions in Europe by 2023, which will enhance their market reach and service offerings. These initiatives are part of their strategy to improve treatment outcomes and patient experiences in cancer care.